

Online Supplementary Material

A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata. *JHEOR*. 2026;13(1):136-140. [doi:10.36469/jheor.2026.159914](https://doi.org/10.36469/jheor.2026.159914)

Table S1: Drug Cost Inputs

Table S2: Base-Case Data Sources

Table S3: Secondary Outcome Results

Table S4: Base-Case Results for Baricitinib 2 or 4 mg and Ritlecitinib 50 mg (Adult Population Only)

Figure S1: Decision-Tree Model Framework

Figure S2: Decision-Tree Model Framework for SALT Response Probabilities for Baricitinib Dosing Schemes and for Ritlecitinib 50 mg (Adult Population Only)

Figure S3: Cost per Responder for (a) Scenario 1 (Baricitinib 2 mg only [all Baricitinib Patients Received 2 mg]), (b) Scenario 2 (Baricitinib 4 mg Only [all Baricitinib Patients Received 4 mg]), and (c) Scenario 3 (Cost Equivalence at Week 52)

This supplementary material has been provided by the authors to give readers additional information about their work.



Supplementary Table S1. Drug cost inputs¹⁶

Drug	National Drug Code	Units/package	Package price, \$	Cost/unit, \$
Ritlecitinib 50 mg	00069-0334-28	28	3,957.69	141.35
Baricitinib 2 mg	00002-4182-30	30	2,739.99	91.33
Baricitinib 4 mg	00002-4479-30	30	5,479.98	182.67

Table S2. Base-case data sources

Input	Base-case source	Decision probabilities
Proportion of patients receiving baricitinib 2 mg and 4 mg	Real-world evidence study using the OMNY database ¹⁷	Baricitinib 2 mg: 67.35% Baricitinib 4 mg: 32.65%
Response to treatment for baricitinib 2 mg and 4 mg	Pivotal phase 3 BRAVE-AA1 and BRAVE-AA2 trials for baricitinib ¹⁴	<u>Baricitinib 2 mg</u> Week 24 SALT $\Delta \geq 30\%$: 31.18% Week 52 SALT ≤ 20 : 48.55%* <u>Baricitinib 4 mg</u> Week 24 SALT $\Delta \geq 30\%$: 46.80% Week 52 SALT ≤ 20 : 65.45%*
Response to treatment for ritilecitinib 50 mg	Pivotal ALLEGRO-2b/3 trial for ritilecitinib ¹³	Week 24 SALT $\Delta \geq 30\%$: 52.10% Week 52 SALT ≤ 20 : 77.27%*
Proportion of baricitinib 2 mg non-responders who up-titrated to baricitinib 4 mg	Real-world evidence study using the OMNY database ¹⁷	37.56%
Drug acquisition costs	Red Book, 2024 ¹⁶	See Table S1

* Of patients with response (SALT $\Delta \geq 30\%$) at Week 24.

Table S3. Secondary outcome results

Outcome	Proportion of patients
Proportion of baricitinib 2-mg patients who missed an opportunity for an effective dose	42.97%
Proportion of all baricitinib patients who missed an opportunity for an effective dose	28.94%
Proportion of baricitinib 2-mg patients who received an inadequate dose for 36 weeks	15.50%

Table S4. Base-case results for the baricitinib 2 or 4 mg and ritlecitinib 50 mg (adult population only)

	Ritlecitinib 50 mg	Baricitinib 2 or 4 mg^a	Absolute difference^b
Total drug costs, \$			
At Week 24	23,746	19,911	3,835
At Week 52	37,730	32,841	4,889
Responders, %^c			
At Week 24 ^d	50.48	36.28	14.20
At Week 52 ^d	38.76	30.63	8.13
Cost per responder, \$			
At Week 24	47,044	54,887	-7,843
At Week 52	97,346	107,217	-9,871


^aRepresents the composite of all patients receiving baricitinib (2 mg and 4 mg).

^bRitlecitinib 50 mg is the reference group for the absolute difference.

^cShorter-term treatment response was defined as Severity of Alopecia Tool (SALT) score relative change from baseline $\geq 30\%$ (SALT $\Delta \geq 30\%$) at Weeks 18 and 24, and longer-term treatment response as absolute SALT score ≤ 20 at Weeks 36 and 52.


^dThe proportion of patients with response was calculated by multiplying probabilities along the same decision tree branch and adding probabilities along different branches. For example, the proportion of baricitinib 2 or 4-mg initiators who achieved SALT $\Delta \geq 30\%$ was calculated as follows: $(32.65\% \times 46.80\%) + (67.35\% \times 31.18\%) = 36.28\%$.

Figure S1. Decision-Tree Model Framework




Abbreviations: AA, alopecia areata; SALT, Severity of Alopecia Tool.

Figure S2. Decision-Tree Model Framework for SALT Response Probabilities for Baricitinib Dosing Schemes and for Ritlecitinib 50 mg (Adult Population Only)



Abbreviations: AA, alopecia areata; SALT, Severity of Alopecia Tool.

Figure S3. Cost per Responder for (a) Scenario 1 (Baricitinib 2 mg only [all Baricitinib Patients Received 2 mg]), (b) Scenario 2 (Baricitinib 4 mg Only [all Baricitinib Patients Received 4 mg]), and (c) Scenario 3 (Cost Equivalence at Week 52)



Shorter-term treatment response was defined as SALT score relative change from baseline $\geq 30\%$ at Weeks 18 and 24, and longer-term treatment response as absolute SALT score ≤ 20 at Weeks 36 and 52. SALT, Severity of Alopecia Tool.